Extracellular Vesicle Core

细胞外囊泡核心

基本信息

批准号：
10630390
负责人：
Sicheng Wen
金额：
$ 21.32万
依托单位：
RHODE ISLAND HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-07-01 至 2028-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10630390
关键词：
Acute Myelocytic Leukemia Aging Alzheimer&apos s Disease Alzheimer’s disease biomarker Area Award Basic Science Binding Biological Markers Biology Bioreactors Blood Body Fluids Bone Marrow Brain Cell secretion Centers of Research Excellence Cerebrospinal Fluid Chronic Clinical Code Collaborations Colon Communities Consultations Core Facility Coupled DNA Data Collection Disease Effectiveness Environment Experimental Designs Feasibility Studies Foundations Funding Grant HIV Harvest Heart Hospitals Immune Immune checkpoint inhibitor Immunoassay Immunooncology Industry Infant Institution Laboratories Large Intestine Lasers Lipids Liver Lung Malignant neoplasm of lung Mediating Medical Oncologist Medical center Membrane Messenger RNA Methods MicroRNAs Molecular Myocardial Ischemia Neurodegenerative Disorders Patients Phase Phenotype Plasma Play Preparation Proteins Protocols documentation Pulmonary Hypertension Research Research Personnel Research Support Rhode Island Robot Role Saliva Services Surface Suspensions System Techniques Time Tissues Translational Research Translations United States National Institutes of Health Universities Untranslated RNA Woman checkpoint therapy clinically significant disorder prevention experience experimental study extracellular vesicles fiber cell instrumentation intercellular communication liquid biopsy nanoparticle novel therapeutic intervention prevent stem cells transcriptome sequencing

项目摘要

Project Summary/Abstract The COBRE Center for Stem Cells and Aging at Rhode Island Hospital established the unique Extracellular Vesicle Core in July 2019. The aims of the Extracellular Vesicle Core are: 1) To provide the research community at Rhode Island Hospital and outside of Rhode Island Hospital with expertise to support research in the field of Extracellular Vesicle (EV). 2) To assist with EV experimental design, data collection, analysis, and storage, as well as preparation for NIH, industry, or foundation grant submissions. 3) To enhance the collaboration and translational research environment in the Rhode Island research community. 4) To become a financially independent Core facility after Phase 3 of the COBRE. The Extracellular Vesicle Core instrumentation mainly consists of two Thermo WX-40 ultracentrifuges, a Tangenx LHV tangential flow system, Applied Biosystems ViiA™ 7 Real-Time PCR System with Twister robot, a Malvern NanoSight NS 500 with two lasers (405nm and 488nm), and a Fiber Cell Systems duet bioreactor. The Extracellular Vesicle Core is a state-of-the-art facility that will continue to enhance collaboration and translational research in the hospital and university communities. In collaboration with clinical doctors from Rhode Island Hospital, our Core has made significant contributions to investigating the clinical significance of EVs as non-invasive “liquid biopsy” biomarkers for tracking the effectiveness of disease therapy. This resulted in a $1.4 million grant in 2020 from Bristol Myers Squibb, where approximately $350,000 was awarded to Dr. Quesenberry’s lab specifically for the Extracellular Vesicle Core. Dr. John Reagan obtained $860,000 from Pfizer for his study of Acute Myeloid Leukemia, where EV-related research was executed through the Extracellular Vesicle Core. Dr. Jill Kreiling got her NIH R01 in 2022, for the study of the feasibility of using extracellular vesicles in saliva as biomarkers for Alzheimer’s disease where $60,000 per year was committed to the Extracellular Vesicle Core in the next five years. In the last three years, the Extracellular Vesicle Core has serviced 18 projects for 22 investigators from 15 different academic departments at five Institutions (Brown University, Rhode Island Hospital, Women and Infants Hospital, the University of Rhode Island, and Providence VA Medical Center). These projects demonstrate that the Extracellular Vesicle Core will continue to play a crucial role in supporting regional projects and facilitating the basic research and the translation of novel therapeutic approaches to the treatment and prevention of disease.

项目摘要/摘要罗德岛医院的干细胞和衰老的毛线中心建立了独特的细胞外囊泡核心于2019年7月。细胞外囊泡核心的目的是：1）提供研究社区在罗德岛医院和罗德岛医院以外细胞外囊泡（EV）。 2）协助EV实验设计，数据收集，分析和存储，作为以及为NIH，行业或基金会赠款提交的准备。 3）增强协作和罗德岛研究界的翻译研究环境。 4）成为财务上的毛绒阶段3阶段之后的独立核心设施。细胞外囊泡核心仪器主要是由两个Thermo WX-40 Ultracentrifuges组成 VIIA™7带有Twister Robot的实时PCR系统，一个Malvern nanosight NS 500，带有两个激光器（405nm和 488nm）和纤维细胞系统二重奏生物反应器。细胞外囊泡核心是一种最新设施将继续增强医院和大学社区的协作和翻译研究。在与罗德岛医院的临床医生合作，我们的核心为研究电动汽车作为非侵入性“液体活检”生物标志物的临床意义疾病疗法的有效性。这在2020年获得了140万美元的赠款 Quesenberry博士专门针对细胞外囊泡核心的实验室授予了约35万美元。约翰·里根（John Reagan）博士从辉瑞（Pfizer）获得了860,000美元的研究，以研究急性髓样白血病通过细胞外囊泡核心进行研究。吉尔·克雷林（Jill Kreiling）博士在2022年获得了NIH R01 研究在唾液中使用细胞外蔬菜作为阿尔茨海默氏病的生物标志物的可行性在未来五年中，每年$ 60,000承诺要向细胞外囊泡核心。在过去的三年中，细胞外囊泡核心为22名来自15个不同学术的研究者提供了18个项目五个机构的部门（布朗大学，罗德岛医院，妇女和婴儿医院，罗德岛大学和普罗维登斯VA医学中心）。这些项目表明细胞外囊泡核心将继续在支持区域项目和支持方面发挥关键作用基础研究以及新型治疗方法的治疗和预防疾病的翻译。